Capricor Therapeutics (CAPR) Interest Expenses (2013 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Interest Expenses of $614675.0 for Q1 2026, up 170.54% year-over-year from $227201.0 in Q1 2025, and up 148.39% quarter-over-quarter from $247466.0 in Q4 2025.
Capricor Therapeutics (CAPR) Interest Expenses (2013 - 2026) Analysis & Trends
Capricor Therapeutics' Interest Expenses history runs 14 years deep, the most recent figure standing at $614675.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 170.54% year-over-year to $614675.0; the TTM figure through Mar 2026 stood at $412421.0 (up 140.64% YoY), while the FY2025 annual figure was $278.2 million, up 173.29% from the prior year.
- Interest Expenses for Q1 2026 stood at $614675.0, up from $247466.0 in the prior quarter.
- The five-year high for Interest Expenses was $118.5 million in Q3 2024, with the low at -$676921.0 in Q4 2024.
- The 5-year median for Interest Expenses is $3.7 million (2023), against an average of $17.2 million.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses sank 226.8% in 2023, then jumped 96505.09% in 2024.
- Capricor Therapeutics' Interest Expenses stood at $470950.0 in 2022, then tumbled by 226.8% to -$597173.0 in 2023, then retreated by 13.35% to -$676921.0 in 2024, then jumped by 136.56% to $247466.0 in 2025, then surged by 148.39% to $614675.0 in 2026.
- Business Quant data shows CAPR's Interest Expenses at $614675.0 in Q1 2026, $247466.0 in Q4 2025, and $33.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | 614,675.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 614,675.00 |
| Mar 31, 2026 | 614,675.00 |
| Dec 31, 2025 | 247,466.00 |
| Dec 31, 2025 | 247,466.00 |
| Sep 30, 2025 | 33.38 Mn |
| Sep 30, 2025 | 33.38 Mn |
| Jun 30, 2025 | 60.57 Mn |
| Jun 30, 2025 | 60.57 Mn |
| Mar 31, 2025 | 227,201.00 |
| Mar 31, 2025 | 227,201.00 |
| Dec 31, 2024 | -676,921.00 |
| Dec 31, 2024 | -676,921.00 |
| Sep 30, 2024 | 118.50 Mn |
| Sep 30, 2024 | 118.50 Mn |
| Jun 30, 2024 | 11.40 Mn |
| Jun 30, 2024 | 11.40 Mn |
| Mar 31, 2024 | 31.03 Mn |
| Mar 31, 2024 | 31.03 Mn |
| Dec 31, 2023 | -597,173.00 |
| Dec 31, 2023 | -597,173.00 |